Specificity and robustness of the mammalian MAPK-IEG network

Biophysical Journal

Volumn 96, Issue 9, 2009, Pages 3471-3482

  Thalhauser, Craig J ^a   Komarova, Natalia L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN FOS; RAF PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; EXPERIMENTAL STUDY; FEEDBACK SYSTEM; GENE EXPRESSION; GENE MUTATION; HYPOTHESIS; IMMEDIATE EARLY GENE; MAMMAL; MATHEMATICAL MODEL; METASTASIS; PREDICTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SIMULATION; STIMULUS; ALGORITHM; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; ONCOGENE; PHYSIOLOGY; TIME;

MAMMALIA;

ALGORITHMS; ANIMALS; COMPUTER SIMULATION; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION; GENE REGULATORY NETWORKS; GENES, FOS; GENES, IMMEDIATE-EARLY; HUMANS; MAMMALS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; TIME FACTORS;

EID: 67650360176     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2008.10.076     Document Type: Article

References (41)

1. Noordman, Y. E., P. A. Jansen, and W. J. Hendriks. 2006. Tyrosine-specific MAPK phosphatases and the control of ERK signaling in PC12 cells. J. Mol. Signal. DOI:10.1186/1750-2187-1-4.
2. D'Alessio, A., L. Cerchia, I. Amelio, M. Incoronato, G. Condorelli, et al. 2007. Shp2 in PC12 cells: NGF versus EGF signaling. Cell. Signal. 19:1193-1200.
3. Santos, S. D., P. J. Verveer, and P. I. Bastiaens. 2007. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat. Cell Biol. 9:324-330.
4. O'Neill, E., and W. Kolch. 2004. Conferring specificity on the ubiquitous Raf/MEK signaling pathway. Br. J. Cancer. 90:283-288.
5. Sun, P., H. Watanabe, K. Takano, T. Yokoyama, J. Fujisawa, et al. 2006. Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells. Genes Cells. 11:1097-1113.
6. Hagan, S., R. Garcia, A. Dhillon, and W. Kolch. 2005. Raf kinase inhibitor protein regulation of Raf and MAPK signaling. Methods Enzymol. 407:248-259.
7. Rath, O., S. Park, H. H. Tang, M. J. Banfield, R. L. Brady, et al. 2008. The RKIP (Raf-1 kinase inhibitor protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cell. Signal. 20:935-941.
8. Murphy, L. O., S. Smith, R. H. Chen, D. C. Fingar, and J. Blenis. 2002. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4:556-564.
9. Komarova, N. L., X. Zou, Q. Nie, and L. Bardwell. 2005. A theoretical framework for specificity in cell signaling. Mol. Sys. Biol. 1: 2005.0023.
10. Bardwell, L., X. Zou, Q. Nie, and N. L. Komarova. 2007. Mathematical models of specificity in cell signaling. Biophys. J. 92:3425-3441.
11. Zou, X., T. Peng, and Z. Pan. 2008. Modeling specificity in the yeast MAPK signaling networks. J. Theor. Biol. 250:139-155.
12. Haugh, J. M. 2002. A unified model for signal transduction reactions in cellular membranes. Biophys. J. 82:591-604.
13. Orton, R. J., O. E. Sturm, V. Vyshemirsky, M. Calder, D. R. Gilbert, et al. 2005. Computational modeling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem. J. 392:249-261.
14. Schoeberl, B., C. Eichler-Jonsson, E. D. Gilles, and G. Muller. 2002. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 20:370-375.
15. Kim, D., O. Rath, W. Kolch, and K. H. Cho. 2007. A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene. 26:4571-4579.
16. Suresh, B. C. V., S. Babar, E. J. Song, and Y. S. Yoo. 2008. Kinetic analysis of the MAPK and PI3K/Akt signaling pathways. Mol. Cells. 25:397-406.
17. Mayawala, K., C. A. Gelmi, and J. S. Edwards. 2004. MAPK cascade possesses decoupled controllability of signal amplification and duration. Biophys. J. 87:L01-L02.
18. Sasagawa, S., Y. Ozaki, K. Fujita, and S. Kuroda. 2005. Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat. Cell Biol. 7:365-373.
19. Kolch, W., M. Calder, and D. Gilbert. 2005. When kinases meet mathematics: the systems biology of MAPK signaling. FEBS Lett. 579:1891-1895.
20. Calder, M., S. Gilmore, and J. Hillston. 2006. Modeling the influence of RKIP on the ERK signaling pathway using the stochastic process algebra PEPA. Lecture Notes Computer Sci. 4230:1-23.
21. Behar, M., H. G. Dohlman, and T. C. Elston. 2007. Kinetic insulation as an effective mechanism for achieving pathway specificity in intracellular signaling networks. Proc. Natl. Acad. Sci. USA. 104:16146-16151.
22. Behar, M., N. Hao, H. G. Dohlman, and T. C. Elston. 2007. Mathematical and computational analysis of adaptation via feedback inhibition in signal transduction pathways. Biophys. J. 93:806-821.
23. Ueda, M., and T. Shibata. 2007. Stochastic signal processing and transduction in chemotactic response of eukaryotic cells. Biophys. J. 93:11-20.
24. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell. 100:57-70.
25. Kolch, W. 2005. Coordinating ERK/MAPK signaling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6:827-837.
26. Hughes, A., L. Gollapudi, T. Sladek, and K. Neet. 2000. Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. J. Biol. Chem. 275:37829-37837.
27. Pumiglia, K., and S. Decker. 1997. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA. 94:448-452.
28. Lee, D., R. Zimmer, S. Lee, and S. Park. 2006. Colored Petri net modeling and simulation of signal transduction pathways. Metab. Eng. 8:112-122.
29. Roberts, P. J., and C. J. Der. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291-3310.
30. Dhillon, A. S., S. Hagan, O. Rath, and W. Kolch. 2007. MAP kinase signaling pathways in cancer. Oncogene. 26:3279-3290.
31. Al-Mulla, F., S. Hagan, W. Al-Ali, S. P. Jacob, A. I. Behbehani, et al. 2008. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J. Clin. Pathol. 61:524-529.
32. Al-Mulla, F., S. Hagan, A. I. Behbehani, M. S. Bitar, S. S. George, et al. 2006. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J. Clin. Oncol. 24:5672-5679.
33. Henry, K. T. M., R. Montesano, S. Zhu, A. B. Beshir, H. H. Tang, et al. 2008. Raf kinase inhibitor protein positively regulates cell-substratum adhesion while negatively regulating cell-cell adhesion. J. Cell. Biochem. 103:972-985.
34. Lee, H. C., B. Tian, J. M. Sedivy, J. R. Wands, and M. Kim. 2006. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology. 131:1208-1217.
35. Angerer, W. 2001. An explicit representation of the Luria-Delbrück distribution. J. Math. Biol. 42:145-174.
36. Komarova, N., L. Wu, and P. Baldi. 2007. The fixed-size Luria-Delbrück model with a nonzero death rate. Math. Biosci. 210:253-290.
37. Welch, D. 2006. Do we need to redefine a cancer metastasis and staging definitions? Breast Dis. 26:3-12.
38. Minoo, P., I. Zlobec, K. Baker, L. Terracciano, J. Jass, et al. 2007. Loss of Raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am. J. Clin. Pathol. 127:820-827.
39. Nakajima, T., M. Moriguchi, Y. Mitsumoto, S. Sekoguchi, T. Nishikawa, et al. 2004. Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma. Mod. Pathol. 17:722-727.
40. Salvucci, M., A. Lemoine, R. Saffroy, D. Azoulay, B. Lepère, et al. 1999. Microsatellite instability in European hepatocellular carcinoma. Oncogene. 18:181-187.
41. Zhang, S., W. Cong, Z. Xian, H. Dong, and M. Wu. 2004. Genomic instability in hepatocellular carcinoma revealed by using the random amplified polymorphic DNA method. J. Cancer Res. Clin. Oncol. 130:757-761.